The new American guidelines for prevention of infective endocarditis
The main changes in the updated American recommendations are as follows:
1. IE prophylaxis for dental procedures should be recommended only for patients with underlying cardiac conditions associated with the highest risk of adverse outcome from IE.
2. For patients with these underlying cardiac conditions, prophylaxis is recommended for all dental procedures that involve manipulation of gingival tissue or the periapical region of teeth or perforation of the oral mucosa.
3. Prophylaxis is not recommended based solely on an increased lifetime risk of acquiring IE.
4. Administration of antibiotics solely to prevent endocarditis is not recommended for patients who undergo a genitourinary or gastrointestinal tract procedure.
A considerable change for patients with cardiac disease
These represent a considerable change and limitation in the current use of endocarditis prophylaxis for Americans with cardiac disease; for instance:
• patients at risk: only those with the highest risk of adverse outcome in case of IE are considered for prophylaxis, including prosthetic cardiac valves, previous endocarditis, unrepaired congenital heart disease, and cardiac transplants who develop cardiac valvulopathy. Most patients with valvular heart disease are no longer considered candidates for antibiotic prophylaxis;
• the dental procedures for which IE prophylaxis is recommended: all procedures involving manipulation of gingival tissue or the periapical region of teeth or perforation of the oral mucosa are considered at risk and need prophylaxis when performed in at-risk patients;
• the GU or GI tract procedures: antibiotic prophylaxis is no longer recommended in these procedures
Limits to applying American guidelines in Europe
Before applying the American guidelines in Europe, we need to consider their limitations. First, the new guidelines are not based on randomised studies.
Second, such radical modifications may be difficult to accept and understand by both patients and practitioners, and much effort will be required to explain them carefully, particularly so that patients understand the shift from focus on dental procedures towards a greater access to dental care and oral health for those with cardiac disease associated with the worst outcome after IE.
Third, these guidelines probably will be followed by a reduction in the number of antibiotic prescriptions for preventing IE in the USA. It will be important to monitor the consequences on the epidemiologic profile of IE in the USA.
Finally, prospective placebo-controlled double-blinded studied of antibiotic prophylaxis of IE in patients at risk of IE remain necessary, as well as additional prospective case-control studies.
The ESC is developing a new version of the 2004 IE guidelines. These will focus on prevention, diagnosis and treatment of IE and are expected by 2009.